Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Sino Biopharmaceutical Limited (SBMFF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Sino Biopharmaceutical Limited $0.76, price $0.70, upside +10.0%, quality 71 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
SB
Some data
Oct 3, 2026
Some data
Oct 3, 2026
Sino Biopharmaceutical Limited
SBMFF · USNeutralQuality growthThe stock looks roughly fairly valued with average quality.
·Fair value $0.7645 · Fairly valued (+10.0%)
✓Quality 71/100
!Mixed Growth (revenue 5y +5.6 %/yr)
!Thin margins · 7.4% net margin (TTM)
✓Low debt · generates free cash flow
✓12.9% dividend yield · Sustainable
!Moderate moat 54/100
!Evidence only medium, so the estimate is less certain
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range $0.2090 – $1.26 · fair‑value band $0.5318 – $0.9972 · the $0.6950 price screens below the $0.7645 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Company profile
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others.
Show more
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anqixin. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH3906; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD208. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Stock analysis
Sino Biopharmaceutical Limited (SBMFF) currently trades at $0.6950, while our model-based Fair Value estimate is $0.7645, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $1.19 per share, and 14 of the 26 models we run sit above the $0.6950 price.
Bear case: the Asset-Based group reads lowest at $0.1700, and 12 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: $0.5318 (bear) to $0.9972 (bull), the price of $0.6950 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sino Biopharmaceutical Limited reported revenue of 31.0B CNY in FY2025 versus 26.9B CNY in FY2021, a compound +3.7%/yr. Reported net income was 2.3B CNY in FY2025, compounding −37.1%/yr from FY2021.
Key figures
Market cap $13.9B · P/E ratio 34.8 · P/S ratio 2.56 · EPS (TTM) $0.0200 · Dividend yield 12.9% · Net margin 7.4% · Return on equity 12.5% · Return on assets (EBIT) 8.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 17% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 10%, SBMFF screens cheaper than that median.
Fair Value models
Bear $0.5318
Fair Value $0.7645
Bull $0.9972
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income
$0.2100
$0.2300
$0.2500
76
FCF DCF
$0.9700
$1.77
$3.77
75
Growth DCF
$0.9500
$1.88
$3.37
75
All 26 models by family
DCF Models
FCF DCF
$0.9700
$1.77
$3.77
75
Owner Earnings
$0.2800
$0.5300
$1.01
72
5Y Revenue Exit
$0.6800
$1.19
$1.90
71
5Y EBITDA Exit
$0.7800
$1.41
$2.23
73
5Y P/E Exit
$0.5300
$0.8500
$1.23
70
10Y Revenue Exit
$0.7500
$1.28
$2.17
65
10Y EBITDA Exit
$0.8300
$1.45
$2.47
66
10Y P/E Exit
$0.6600
$1.03
$1.57
63
Earnings-Based
Graham-Dodd
$0.1300
$0.7600
$1.06
63
Lynch FV
$0.2200
$0.3100
$0.4000
61
PEG = 1.0
$0.2200
$0.3100
$0.4000
57
EPV
$0.4400
$0.5100
$0.5700
74
Dividend Discount
Gordon GGM
$0.1200
$0.2400
$0.3800
66
DDM Multi-Stage
$0.1200
$0.2000
$0.2500
67
Multiples
P/E Multiple
$0.3200
$0.4200
$0.5300
63
P/S Multiple
$0.2400
$0.3200
$0.4100
58
P/B Multiple
$0.2400
$0.3200
$0.4100
55
EV/EBIT
$0.7500
$0.9800
$1.22
66
EV/EBITDA
$0.7300
$0.9600
$1.19
67
EV/Revenue
$0.5400
$0.7600
$0.9800
54
Asset-Based
NCAV (Graham)
$0.1300
$0.1700
$0.2600
54
Growth DCF
Growth DCF
$0.9500
$1.88
$3.37
75
Rev-Margin DCF
$0.6800
$1.17
$1.86
71
Economic Profit
Residual Income
$0.2100
$0.2300
$0.2500
76
ROIC Compounder
$0.5200
$0.7300
$1.03
71
Growth Earnings
Growth-Adj P/E
$0.3200
$0.4600
$0.6000
67
Notify me when SBMFF reaches fair value
Put SBMFF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
71/100
Of which business quality 69 · Market factors (momentum, volatility) 71
Profitability
38
Margins and returns on capital today
Quality Growth
49
Are margins and returns improving?
Cashflow
94
Earnings quality: real cash, not paper profit
Fin. Strength
61
Balance sheet, leverage, solvency risk
Investment
82
Disciplined investing over empire-building
Low Volatility
46
Calm price path (market factor)
Momentum
90
Price trend over the last 3–12 months (market factor)
52W Momentum
70
Distance to the 52-week high (market factor)
Net Issuance
97
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
75/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Start year 2020 (pandemic). Over 10 years: +9.8% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+0.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.7%
Dividend (yield on the price)12.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−12.7% vs 3.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 21%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −7.5% a year for the price and +7.2% for the forecasts.
Forecast 2026 (sales)+16.2%
Forecast 2027 (sales)+8.5%
Projected 2028 (sales)+7.7%
Projected 2029 (sales)+6.9%
Projected 2030 (sales)+6.1%
Watch SBMFF, get fair value alerts →
Compare Sino Biopharmaceutical Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Sino Biopharmaceutical Limited (SBMFF) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.7645 versus a price of $0.6950, about +10% upside (undervalued).
What is the fair value of SBMFF?
Our model-based fair value for Sino Biopharmaceutical Limited is $0.7645 (as of Oct 3, 2026), built from audited fundamentals. The current price: $0.6950.
What is the quality score of SBMFF?
Sino Biopharmaceutical Limited has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sino Biopharmaceutical Limited (SBMFF)?
Our model-based price target is the fair value of $0.7645 (as of Oct 3, 2026) from 26 valuation models. Cautious scenario $0.5318, optimistic scenario $0.9972. It is a calculation from audited fundamentals, not an analyst target.
What is the Sino Biopharmaceutical Limited stock forecast for 2026?
Our models put fair value at $0.7645, about +10% upside versus a price of $0.6950 (undervalued). Cautious scenario $0.5318, optimistic scenario $0.9972. The calculation is refreshed regularly with new filings.
What is the revenue of Sino Biopharmaceutical Limited (SBMFF)?
Sino Biopharmaceutical Limited reported trailing-twelve-month revenue of about 31.8B CNY (latest available figure, as of Oct 3, 2026).
Does Sino Biopharmaceutical Limited pay a dividend?
Sino Biopharmaceutical Limited currently shows a dividend yield of about 12.95% relative to its recent price (as of Oct 3, 2026).
What growth is priced into Sino Biopharmaceutical Limited (SBMFF)?
For today's price to be fair in a discounted-cash-flow model, Sino Biopharmaceutical Limited would have to grow free cash flow by -5.9 % per year for five years (discount rate 8.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.6 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of SBMFF use?
Our models discount Sino Biopharmaceutical Limited at 8.4 %: a base by market capitalisation (large), damped by beta 0.62, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sino Biopharmaceutical Limited that is -5.9 % per year a year over ten years, using the same discount rate (8.4 %) and the same formula as our fair value.
How much growth has Sino Biopharmaceutical Limited (SBMFF) delivered so far?
Over the past 5 years revenue at Sino Biopharmaceutical Limited grew +5.6 % a year. The price currently implies -5.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sino Biopharmaceutical Limited (SBMFF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Sino Biopharmaceutical Limited (-5.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sino Biopharmaceutical Limited (SBMFF)?
The free-cash-flow yield on the price is 9.02 %: that much free cash flow Sino Biopharmaceutical Limited produces per unit of market value. When it exceeds the discount rate of our models (8.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sino Biopharmaceutical Limited (SBMFF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sino Biopharmaceutical Limited it is $0.7645 per share (as of Oct 3, 2026), against a price of $0.6950. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Sino Biopharmaceutical Limited stock overvalued or undervalued in 2026?
As of Oct 3, 2026, SBMFF trades below its calculated fair value: price $0.6950, fair value $0.7645, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SBMFF?
No. The price is what the market pays today ($0.6950); the fair value is what the company's own numbers justify ($0.7645). For Sino Biopharmaceutical Limited the two are $0.0695 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sino Biopharmaceutical Limited worth?
The market values Sino Biopharmaceutical Limited at about $13.9B (market capitalisation, as of Oct 3, 2026). Per share that is $0.6950; our models calculate a fair value of $0.7645 per share.
What do the bullish and bearish scenarios say about SBMFF?
Our models span a range for Sino Biopharmaceutical Limited: cautious scenario $0.5318, base $0.7645, optimistic $0.9972 per share (as of Oct 3, 2026, price $0.6950). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is SBMFF from its 52-week high?
Sino Biopharmaceutical Limited trades at $0.6950, about 35% below its 52-week high of $1.07 and 17% above the low of $0.5930 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.7645 is for.
Which stocks are comparable to Sino Biopharmaceutical Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sino Biopharmaceutical Limited stock attractive at the current price?
The data as of Oct 3, 2026: price $0.6950, calculated fair value $0.7645 (+10%), Quality Score 71/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SBMFF calculated?
We run Sino Biopharmaceutical Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.7645, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sino Biopharmaceutical Limited currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sino Biopharmaceutical Limited (SBMFF)?
The closing price on Oct 2, 2026 was $0.6950. Our model-based fair value is $0.7645, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sino Biopharmaceutical Limited right now?
A fairly wide model range ($0.5318 to $0.9972) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Sino Biopharmaceutical Limited (SBMFF) come from?
Earnings per share at Sino Biopharmaceutical Limited grew +5.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +9.0 %, EBIT margin −2.0 %, tax rate −0.5 %, residual (interest, one-offs) −0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sino Biopharmaceutical Limited
How large is the market capitalisation of Sino Biopharmaceutical Limited (SBMFF)?
The market capitalisation of Sino Biopharmaceutical Limited is $13.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Sino Biopharmaceutical Limited (SBMFF)?
The price-to-earnings ratio of Sino Biopharmaceutical Limited is 34.8. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Sino Biopharmaceutical Limited (SBMFF)?
The price-to-sales ratio of Sino Biopharmaceutical Limited is 2.56 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sino Biopharmaceutical Limited (SBMFF)?
Earnings per share at Sino Biopharmaceutical Limited are $0.0200 (price ÷ EPS = P/E 34.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sino Biopharmaceutical Limited (SBMFF)?
The dividend yield of Sino Biopharmaceutical Limited is 12.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sino Biopharmaceutical Limited (SBMFF)?
The net margin of Sino Biopharmaceutical Limited is 7.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sino Biopharmaceutical Limited (SBMFF)?
The return on equity (ROE) of Sino Biopharmaceutical Limited is 12.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sino Biopharmaceutical Limited (SBMFF)?
On an EBIT basis the return on assets of Sino Biopharmaceutical Limited is 8.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sino Biopharmaceutical Limited (SBMFF)?
The operating margin of Sino Biopharmaceutical Limited is 20.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sino Biopharmaceutical Limited (SBMFF)?
Revenue at Sino Biopharmaceutical Limited is growing +9.8% versus a year earlier (3y avg +6.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sino Biopharmaceutical Limited (SBMFF)?
Earnings per share at Sino Biopharmaceutical Limited are growing +14.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Sino Biopharmaceutical Limited (SBMFF) carry?
The net debt of Sino Biopharmaceutical Limited is 3.9B CNY (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.